All Stories

  1. Targeting the “PVR–TIGIT axis” with immune checkpoint therapies

    Article • F1000Research, May 2020, Faculty of 1000, Ltd.

    daniel olive

  2. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma

    Article • OncoImmunology, September 2019, Taylor & Francis

    daniel olive

  3. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma

    Article • OncoImmunology, May 2019, Taylor & Francis

    daniel olive, Anne-Sophie CHRETIEN

  4. A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system

    Article • OncoImmunology, April 2019, Taylor & Francis

    Aurelien Corneau, daniel olive

  5. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

    Article • OncoImmunology, February 2019, Taylor & Francis

    daniel olive, Anne-Sophie CHRETIEN

  6. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy

    Article • Expert Opinion on Therapeutic Targets, March 2018, Taylor & Francis

    daniel olive

  7. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation

    Article • European Journal of Immunology, April 2017, Wiley

    Matthias Kreiss, daniel olive

  8. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML

    Article • OncoImmunology, March 2017, Taylor & Francis

    daniel olive, Anne-Sophie CHRETIEN